fröhlich eingekauft...warum wohl ???
http://zolmax.com/investing/...rapeutics-holdings-inc-ptx/624279.html
Brean Capital Reaffirms “Buy” Rating for Pernix Therapeutics Holdings Inc (PTX)
Pernix Therapeutics Holdings Inc logoBrean Capital reiterated their buy rating on shares of Pernix Therapeutics Holdings Inc (NYSE:PTX) in a report released on Friday, MarketBeat Ratings reports. They currently have a $3.00 price target on the specialty pharmaceutical company’s stock.
A number of large investors recently bought and sold shares of the company. Morgan Stanley increased its stake in Pernix Therapeutics Holdings by 48,456.0% in the fourth quarter. Morgan Stanley now owns 5,160,043 shares of the specialty pharmaceutical company’s stock worth $15,222,000 after buying an additional 5,149,416 shares during the period. Bank of Montreal Can increased its stake in Pernix Therapeutics Holdings by 29.3% in the fourth quarter. Bank of Montreal Can now owns 1,045,279 shares of the specialty pharmaceutical company’s stock worth $3,083,000 after buying an additional 236,832 shares during the period. Millennium Management LLC increased its stake in Pernix Therapeutics Holdings by 150.9% in the fourth quarter. Millennium Management LLC now owns 872,636 shares of the specialty pharmaceutical company’s stock worth $2,574,000 after buying an additional 524,801 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Pernix Therapeutics Holdings by 17.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,516,585 shares of the specialty pharmaceutical company’s stock worth $1,592,000 after buying an additional 226,151 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Pernix Therapeutics Holdings by 72.9% in the first quarter. Acadian Asset Management LLC now owns 567,542 shares of the specialty pharmaceutical company’s stock worth $595,000 after buying an additional 239,329 shares during the period.
Several other research firms have also issued reports on PTX. Zacks Investment Research lowered shares of Pernix Therapeutics Holdings from a hold rating to a sell rating in a report on Friday, April 15th. Needham & Company LLC lowered shares of Pernix Therapeutics Holdings from a buy rating to a hold rating in a report on Thursday, March 10th. Oppenheimer lowered shares of Pernix Therapeutics Holdings from an outperform rating to a market perform rating in a report on Wednesday, March 16th. S&P Equity Research decreased their price objective on shares of Pernix Therapeutics Holdings from $1.37 to $1.12 in a report on Wednesday, March 23rd. Finally, JMP Securities decreased their price objective on shares of Pernix Therapeutics Holdings from $8.00 to $6.00 and set a market outperform rating for the company in a report on Wednesday, March 2nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Pernix Therapeutics Holdings has a consensus rating of Hold and a consensus target price of $5.98.
Shares of Pernix Therapeutics Holdings (NYSE:PTX) traded down 17.8074% on Friday, hitting $0.4071. The stock had a trading volume of 4,049,657 shares. The firm’s market capitalization is $24.86 million. Pernix Therapeutics Holdings has a 1-year low of $0.41 and a 1-year high of $7.10. The firm has a 50 day moving average of $0.93 and a 200-day moving average of $2.09.
Pernix Therapeutics Holdings (NYSE:PTX) last released its earnings results on Thursday, May 5th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $32.50 million for the quarter, compared to analysts’ expectations of $44.55 million. Equities analysts predict that Pernix Therapeutics Holdings will post ($0.04) earnings per share for the current year.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
|
Thread abonnieren
